 Solid Biosciences Inc NASDAQ: SLDB reported interim functional, biomarker data, and patient-reported outcome measures from its ongoing IGNITE Phase 12 trial of its lead gene therapy candidate, SGT-001 in Duchenne muscular dystrophy DMD. While IGNITE-DMD was designed to assess the microdystrophin protein expression and distribution, the company instead chose to highlight the functional and patient-reported outcomes at the 12-month mark. 